

BiocurePharm, Korea ("BPK") Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - September 10, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that they have been actively pursuing Joint Venture opportunities with several overseas companies including a strategic alliance with the University of Malaya Hospital to move forward with a compassionate human clinical trial (CT) before the end of 2020.

BPK is fully ready to implement a clinical trial in Korea once the Investigational New Drug (IND) approval is obtained from Korean FDA, which is expected imminently. BPK is also pleased to announce that there was positive efficacy of its CAR T, from a recent clinical trial at one of major hospitals in China. The trial demonstrated a success rate of 94% of Complete Remission (CR) from 59 ALL (Acute Lymphocyte Leukemia) patients out of a total of 63 patients in terminal stage of ALL.

Concurrently, BPK has been in discussion with two major hospitals in Korea, Asan Medical Center and The Catholic University of Korea, Seoul St. Mary's Hospital to commence a clinical trial of CAR T in Korea. Upon obtaining IND approval from the Korean FDA, these two hospitals are prepared to begin a clinical trial.

BPK is working on additional animal research requested by the Korean FDA to satisfy their guidelines for clinical trial. All requested tests shall be completed by the end of November 2020 and the human clinical trial ("CT") is expected to start by late 2020 or early 2021.

Dr. Sang Mok Lee, CEO and President of Biocure and BPK, states: "I am pleased to report that all members of CURE and BPK are working hard to move forward our CAR T project so that we can supply CAR T for ALL patients in terminal stage at far more affordable prices than the ones from current suppliers. I strongly believe that our hard work and dedication will be a pathway to save more ALL patients' lives by offering more competitive prices and making recovery possible. Biocure will continue to make every effort to commercialize CAR-T products as soon as possible to meet the expectations of our shareholders."

About Biocure

Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis ("MS") Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine, and a hair growth production product.

ON BEHALF OF THE BOARD OF DIRECTORS

/S/ "SANG MOK LEE"
CEO and Director

For further information, please contact:

Biocure Technology Inc. Telephone: 604-609-7146, or info@biocuretech.com

Certain statements in this news release, which are not historical in nature, constitute "forward looking statements" within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company's proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management's current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the "CSE") nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.



To view the source version of this press release, please visit
<https://www.newsfilecorp.com/release/63553>